Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study

Blood 2026

View at publisher
Authors: Andre Maurice Small, Siddharth M. Patel, Robert P Giugliano, David A. Morrow, Erica L. Goodrich, Bruce Hug, Sanobar Parkar, Shih-Ann Chen, Shaun G Goodman, Boyoung Joung, Róbert Gábor Kiss, Wojciech Wojakowski
+4 more Jeffrey I Weitz, Dan Bloomfield, Marc S Sabatine, Christian Thomas Ruff
DOI: 10.1182/blood.2026033829
Cited by: 1
References: 11

Abstract

ABSTRACT: This prespecified AZALEA-TIMI 71 analysis showed that prior oral anticoagulation (OAC) experience indicates bleeding risk in atrial fibrillation. The factor XI inhibitor abelacimab reduced bleeding regardless of prior OAC experience, with potentially greater absolute benefit among OAC-naïve patients. This trial was registered at www.ClinicalTrials.gov as NCT04755283.

Fields of Study & Subjects

Coagulation Bradykinin Polyphosphates and Angioedema Hemophilia Treatment and Research Thyroid and Parathyroid Surgery

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
148
Issue
6
Pages
789–792
Publication date
29 May 2026
Language
EN